Clinical Trials Logo

Filter by:
NCT ID: NCT05797662 Not yet recruiting - Kaposi Sarcoma Clinical Trials

A Study of Propranolol to Treat Kaposi Sarcoma

Start date: July 1, 2025
Phase: Phase 2
Study type: Interventional

A clinical study of propranolol for the treatment of Kaposi Sarcoma in children and adults. This study will be an open-label single armed treatment trial that will test the effectiveness and the safety of treating Kaposi Sarcoma with propranolol.

NCT ID: NCT05641272 Not yet recruiting - Allergic Rhinitis Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract

MM09-SLIM
Start date: November 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Prospective, randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of polymerized and mannan conjugated allergen extract of Dermatophagoides for the treatment of allergic rhinitis/rhinoconjunctivitis with or without asthma. The main objective of the clinical trial is to evaluate the clinical efficacy of the investigational medicinal product, administered sublingually, compared to placebo for the treatment of moderate-severe rhinitis/rhinoconjunctivitis with or without mild to moderate asthma and controlled using the Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (R-CSMS).

NCT ID: NCT05630898 Not yet recruiting - Clinical trials for Congenital Cytomegalovirus

Congenital Cytomegalovirus: Prevalence in Buenos Aires City (cCMV Prevalence)

cCMV
Start date: April 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to recognise the prevalnce of congenital cytomegalovirus (cCMV) and to follow up positive babies until 12 months The main questions it aims to answer are: pevalence of cCMV, cCMV clinicals outcomes during the first year of life. Participants will be screened with a salive swab for CMV DNA. Babies with positive results will be follow up for one year.

NCT ID: NCT05576246 Not yet recruiting - Healthy Volunteers Clinical Trials

Airway Occlusion Measured During Non-invasive Ventilation to Assess Respiratory Effort

Start date: October 30, 2022
Phase:
Study type: Observational

Non-invasive ventilation (NIV) is extensively used in critical care settings and emergency departments for a variety of aetiologies but specially for acute respiratory failure (ARF). It eliminates morbidity related to the endotracheal tube and use of sedatives so it reduces intensive care unit (ICU) complications; however, on the other hand, the harmful effects of spontaneous breathing through the intensity of inspiratory effort may predispose the patient to the onset of self-inflicted lung injury (SILI). Therefore, measuring the level of inspiratory effort is recommended.The aim of this proof-of-concept physiological study was to describe the correlation between ΔPocc measured on the ventilator and ΔPes in healthy subjects with NIV.

NCT ID: NCT05500729 Not yet recruiting - Healthy Volunteers Clinical Trials

Hamstring/Quadriceps Ratio in CrossFit

HQCROSS
Start date: August 22, 2022
Phase:
Study type: Observational

Crossfit® is a high-intensity physical training plan based on a program that includes exercises such as running, weight lifting and gymnastic movements. It focuses on the development of 10 physical qualities: strength, balance, cardiovascular and respiratory endurance, coordination, power, flexibility, agility, speed, precision and muscular endurance.Unfortunately, research on its effects is still at the beginning. The time of each session is one hour, which is divided into a warm-up of 10-30 minutes, strength training or skills, endurance work and finally a recovery phase, mobility and stretching. These types of exercises are incorporated into group training sessions called Workout of The Day (WOD). Muscular strength is the action produced by a muscle or muscle group against resistance. It is one of the fundamental physical qualities for activities of daily living. Digital isometric dynamometry is a tool to evaluate maximum voluntary isometric contraction (MVIC). Hamstring muscles are responsible for hip extension and knee flexion. Moreover, they are the main protectors against anterior knee subluxation due to their action in conjunction with the anterior cruciate ligament (ACL).The quadriceps is one of the largest and most powerful muscles of the human body. The ratio between hamstrings and quadriceps muscles has a strong correlation with lower limb injuries. This ratio, known as "H:Q" has proved to be the most reliable indicator to quantify a neuromuscular decompensation that causes an injury and, in addition, it is used as a prognostic indicator.

NCT ID: NCT05477953 Not yet recruiting - Chagas Disease Clinical Trials

An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

Start date: June 30, 2024
Phase:
Study type: Observational

This is an observational study in which data from women with Chagas disease who will take or have already taken nifurtimox during pregnancy and the impact on their babies are studied. Chagas disease is an inflammatory, infectious disease caused by the parasite Trypanosoma cruzi. This parasite is mainly spread by insects called triatomine bug. If Chagas disease is left untreated, it can later cause e.g. serious heart and digestive problems. Nifurtimox has been used for more than 50 years to treat Chagas disease in children and adults. It is not recommended to be used during pregnancy as data from animal studies indicate that it may harm the baby. Currently, there are not enough data to know if this is also the case in humans. In this study, researchers want to collect data on the safety of nifurtimox use in pregnant women. To do this, researchers will collect the following information: - Birth defects (abnormal and problematic structures or functions, a child is born with) - Pregnancy outcomes (like live birth, preterm birth, still birth/death of the unborn baby, miscarriage, or abortion) - Certain health problems of the child up to 12 months of age - Certain health problems of the women experienced during pregnancy The data will be collected from different sources including telephone calls with the women or their doctor, CRFs (case reprt forms) or from medical records The researchers will compare the proportion of children with birth defects, pregnancy outcomes or certain health problems of the child or the women during pregnancy with available data on these outcomes in the general population. The study will run for approximately 10 years.

NCT ID: NCT05289609 Not yet recruiting - Clinical trials for Liver Transplant Disorder

Developing Prediction Models for Allograft Failure After Liver Transplantation

IMPROVEMENT
Start date: April 1, 2022
Phase:
Study type: Observational

Prompt identification of allograft failure (AF) is highly desirable to address patients to liver retransplantation, in order to maximize results and preserve patients safety. Recently, sophisticated kinetic models became available, offering the possibility to predict 90-day AF with unprecedented accuracy, by computing data from the first 10 days after liver transplant (LT). The growing utilization of extended criteria and cardiac death donors stimulates the transplant community to further refine such predictive models and validate them on a larger scale population of patients across the nations. This study aims to develop new algorithms for the timely prediction of AF at 90 and 365 days using a prospective international cohort from high-volume centers, to validate them on a large retrospective cohort, to identify the best time for retransplantation, to stratify the risk of AF according to the graft type (i.e. DBD, ECD, DCD, LD), to weigh the effect of risk-mitigation strategies, and to assess the correlation with post-LT morbidity and mortality.

NCT ID: NCT05275322 Not yet recruiting - Clinical trials for To Assess the Clinical Usefulness and Acceptability Level of the UP Online Group Format in Argentina as Well as Participants' Satisfaction

Online Group Psychological Intervention for People With Emotional Disorders

Start date: March 2022
Phase: N/A
Study type: Interventional

Participants will receive an online synchronous group therapy based on the Unified Protocol (UP) model for 11 subsequent weeks, with 90-minute meetings. After every session, they will be sent the chapter with the notions addressed in the session from the UP's patient manual (Barlow et al., 2011) and the scales to work with during the week. Participants in the waiting list will complete the evaluation scales at the same time as people in the intervention group (before the intervention, in the middle, after the intervention, three months after and six months after). After this period they will receive the group therapy based on the UP. The group admission criteria are: 1) being 18 years old or older; 2) submitting the informed consent; 3) agreeing to participate in all the scheduled sessions; 4) agreeing to have the sessions recorded (both audio and video) for oversight purposes; 5) submitting a primary diagnosis of an anxiety disorder (e.g., panic disorder; agoraphobia; social anxiety disorder; generalized anxiety disorder; unspecific anxiety disorder), unipolar depression (major depressive disorder; dysthymia), obsessive-compulsive disorder, or post-traumatic stress disorder, according to DSM criteria and disrupting individuals' daily life or causing significant discomfort. The group exclusion criteria are: 1) comorbidity with psychotic disorders, bipolar disorder, eating disorders, borderline personality disorder, or active severe suicidal ideation, and 2) currently receiving pharmacological treatment. All candidates who are not included in the group will be informed of this decision and will be given information on places to seek treatment. Evaluations will be carried out via video calls on the Google Meet platform, using the MINI (Ferrando et al., 2000) and SCID-II (Grilo, Anez & McGlashan, 2003) diagnostic interviews.

NCT ID: NCT04831632 Not yet recruiting - Clinical trials for Colorectal Neoplasms

Diagnostic Performance Assessment of Qualitative Ifobt and Quantitative Ifobt for Advanced Neoplastic

Start date: May 1, 2021
Phase:
Study type: Observational

In Argentina, there is vast experience in qualitative iFOBT population screening that is part of the CRC Prevention and Early Detection National Program. The screening's cut-off point is at 50 ng/mL buffer. Its positivity rate for 2019 has been an average of 26.15%, over the double of the one reported in the international literature (7.5-11%) for this cut-off point (1). There are no studies that assess such technology and suggest an appropriate cut-off point for this population. The goal of this study is to assess the diagnostic performance of the qualitative iFOBT used in the present and the quantitative iFOBT with various cut-off points for advanced neoplastic wound screening (colorectal cancer and advanced adenoma) in an Argentine patient cohort.

NCT ID: NCT04640064 Not yet recruiting - Type1diabetes Clinical Trials

Hb A1C Pre and Post Confinement in Latin American Children With Type 1 Diabetes: Dulce Study Group

Start date: November 22, 2020
Phase:
Study type: Observational

A multicenter retrospective observational study among children with type 1 diabetes will be performed. The Objective of this study will be to determine a) the association between the increase in Hba1c in children with type 1 diabetes and confinement due to the COVID 19 pandemic. b) the association between the frequency of patient care during social confinement and the Hba1c values. Different centers from Latin America including Argentina, Peru, Panama, Chile, and Ecuador will participate in this study. Children younger than 17 years with a diagnosis of type 1 diabetes prior to 2018 will be included. Data from the medical records of the participating centers will be collected on the Hb A1c value before and after confinement (6 months completed). The initial (base) value will be taken as a value of HbA1c registered in the patient's Clinical History for the year 2018, 2019, and 2020 pre and post quarantine (Sep-Oct-Nov) 2020, considering compliance with six months of quarantine. Hb A1c should have been performed in the same institution or with the same methods in order to avoid bias.